Trial Profile
A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment of patients with hepatocellular carcinoma that are candidates for locoregional therapies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms NASIR-HCC
- 24 Jun 2023 Results of sub analysis (n=32) assessing health related quality of life (HRQoL) of patients with unresectablehepatocellular carcinoma (uHCC) during treatment with SIRT andthe anti-programmed cell death-1 (PD1) agent nivolumab presented at the European Association for the Study of the Liver Congress 2023
- 03 Nov 2020 Status changed from active, no longer recruiting to completed.
- 14 Sep 2020 Results presented in the Sirtex Medical Media Release.